endometrial cancer
Conditions
Interventions
None listed
Sponsors
SRL Medisearch Inc.
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patients who are diagnosed as the advanced recurrent endometrial cancer by surgery or by histologically or cytological biopsy and there is no standard chemotherapy choices (not be responsive to the existing chemotherapy). 2) Female patients over 20 years old at the time of written informed consent. 3) Patients who agreed on the informed consent including document offer in the study. 4) The patient capable of providing a blood and tumor tissue samples which is collected and stored at the time of diagnosis or surgery.
Exclusion criteria
Exclusion criteria: 1) Patients judged by their physician to be unfit to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| [Blood] Gene mutation and chromosome copy number abnormality analysis using the Droplet Digital PCR. PIK3CA gene mutation, AKT1 gene mutation and amplification, AKT2 gene amplification. [FFPE tumor tissue] Analysis using Droplet Digital PCR and PCR. PIK3CA gene mutation, AKT1 gene mutation and amplification, AKT2 gene amplification. | — |
Secondary
| Measure | Time frame |
|---|---|
| [FFPE tumor tissue] Gene analysis using NGS Target gene will be updated in the future depending on the contents of the chip. | — |
Countries
Japan
Contacts
Public ContactToru Ichiyanagi
SRL Medisearch Inc. Clinical Research Development ECGA STUDY secretariat
Outcome results
None listed